Inovio Pharmaceuticals Inc.’s meteoric rise on the back of hype for a vaccine to treat the coronavirus drew the ire of noted short-seller Citron Research, as the firm slapped a $2 target on the drug maker.
“SEC should immediately HALT this stock and investigate the ludicrous and dangerous claim that they designed a vaccine in 3 hours,” the tweet said. “This has been a serial stock promotion for years. This will trade back to $2. Investors have been warned.”
